Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
First phase 1 starters challenge Pluvicto and Revolution
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
